Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Open Access
- 17 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5), e63773
- https://doi.org/10.1371/journal.pone.0063773
Abstract
To investigate the efficacy of melatonin compared to placebo in improving sleep parameters in patients with primary sleep disorders. PubMed was searched for randomized, placebo-controlled trials examining the effects of melatonin for the treatment of primary sleep disorders. Primary outcomes examined were improvement in sleep latency, sleep quality and total sleep time. Meta-regression was performed to examine the influence of dose and duration of melatonin on reported efficacy. Adults and children diagnosed with primary sleep disorders. Melatonin compared to placebo. Nineteen studies involving 1683 subjects were included in this meta-analysis. Melatonin demonstrated significant efficacy in reducing sleep latency (weighted mean difference (WMD) = 7.06 minutes [95% CI 4.37 to 9.75], Z = 5.15, p<0.001) and increasing total sleep time (WMD = 8.25 minutes [95% CI 1.74 to 14.75], Z = 2.48, p = 0.013). Trials with longer duration and using higher doses of melatonin demonstrated greater effects on decreasing sleep latency and increasing total sleep time. Overall sleep quality was significantly improved in subjects taking melatonin (standardized mean difference = 0.22 [95% CI: 0.12 to 0.32], Z = 4.52, p<0.001) compared to placebo. No significant effects of trial duration and melatonin dose were observed on sleep quality. This meta-analysis demonstrates that melatonin decreases sleep onset latency, increases total sleep time and improves overall sleep quality. The effects of melatonin on sleep are modest but do not appear to dissipate with continued melatonin use. Although the absolute benefit of melatonin compared to placebo is smaller than other pharmacological treatments for insomnia, melatonin may have a role in the treatment of insomnia given its relatively benign side-effect profile compared to these agents.Keywords
This publication has 40 references indexed in Scilit:
- Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysisBMC Research Notes, 2012
- Insomnia: evidence-based approaches to assessment and managementClinical Medicine, 2011
- Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term responseCurrent Medical Research and Opinion, 2010
- A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorderJournal of Sleep Research, 2010
- Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCTPsychopharmacology, 2010
- Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomesCurrent Medical Research and Opinion, 2007
- The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTsJournal of General Internal Medicine, 2007
- The basic physiology and pathophysiology of melatoninSleep Medicine Reviews, 2005
- The Prevalence, Cost Implications, and Management of Sleep Disorders: An OverviewSleep and Breathing, 2002
- Melatonin and insomniaJournal of Sleep Research, 1996